Liposomal doxorubicin: Effective treatment for pediatric desmoid fibromatosis.

Ananth, Prasanna; Werger, Annette; Voss, Stephan; Rodriguez-Galindo, Carlos; Janeway, Katherine A

Ananth, Prasanna; Werger, Annette; Voss, Stephan; Rodriguez-Galindo, Carlos; Janeway, Katherine A.

Afiliação

Ananth P; Department of Pediatric Hematology/Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.
Werger A; Department of Pediatric Hematology/Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.
Voss S; Department of Radiology, Boston Children's Hospital, Boston, Massachusetts.
Rodriguez-Galindo C; Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, Tennessee.
Janeway KA; Department of Pediatric Hematology/Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.

Pediatr Blood Cancer ; 64(7)2017 Jul.

Article em En | MEDLINE | ID: mdl-27905688

Assuntos

Antibióticos Antineoplásicos/uso terapêutico; Doxorrubicina/análogos & derivados; Fibromatose Agressiva/tratamento farmacológico; Adolescente; Criança; Pré-Escolar; Doxorrubicina/uso terapêutico; Feminino; Humanos; Masculino; Polietilenoglicóis/uso terapêutico; Estudos Retrospectivos

Palavras-chave

RECIST; desmoid fibromatosis; liposomal doxorubicin; pediatric; progression-free interval

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doxorrubicina / Fibromatose Agressiva / Antibióticos Antineoplásicos Tipo de estudo: Observational_studies Limite: Adolescent / Child / Child, preschool / Female / Humans / Male Idioma: En Revista: Pediatr Blood Cancer Assunto da revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google